Research ExplorerPublicationsPlasma S100P level as a novel prognostic marker of metastati...

Plasma S100P level as a novel prognostic marker of metastatic breast cancer

Standard

Plasma S100P level as a novel prognostic marker of metastatic breast cancer. / Peng, Cike; Chen, Hongda; Wallwiener, Markus; Modugno, Caroline; Cuk, Katarina; Madhavan, Dharanija; Trumpp, Andreas; Heil, Jörg; Marmé, Frederik; Nees, Juliane; Riethdorf, Sabine; Schott, Sarah; Sohn, Christof; Pantel, Klaus; Schneeweiss, Andreas; Yang, Rongxi; Burwinkel, Barbara.

In: BREAST CANCER RES TR, Vol. 157, No. 2, 04.05.2016, p. 329-38.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Peng, C, Chen, H, Wallwiener, M, Modugno, C, Cuk, K, Madhavan, D, Trumpp, A, Heil, J, Marmé, F, Nees, J, Riethdorf, S, Schott, S, Sohn, C, Pantel, K, Schneeweiss, A, Yang, R & Burwinkel, B 2016, 'Plasma S100P level as a novel prognostic marker of metastatic breast cancer', BREAST CANCER RES TR, vol. 157, no. 2, pp. 329-38. https://doi.org/10.1007/s10549-016-3776-1

APA

Peng, C., Chen, H., Wallwiener, M., Modugno, C., Cuk, K., Madhavan, D., Trumpp, A., Heil, J., Marmé, F., Nees, J., Riethdorf, S., Schott, S., Sohn, C., Pantel, K., Schneeweiss, A., Yang, R., & Burwinkel, B. (2016). Plasma S100P level as a novel prognostic marker of metastatic breast cancer. BREAST CANCER RES TR, 157(2), 329-38. https://doi.org/10.1007/s10549-016-3776-1

Vancouver

Peng C, Chen H, Wallwiener M, Modugno C, Cuk K, Madhavan D et al. Plasma S100P level as a novel prognostic marker of metastatic breast cancer. BREAST CANCER RES TR. 2016 May 4;157(2):329-38. https://doi.org/10.1007/s10549-016-3776-1

Bibtex

@article{921ad2453b1e4a61a637aa0f749ecc1d,
title = "Plasma S100P level as a novel prognostic marker of metastatic breast cancer",
abstract = "Metastasis is the main cause of death in breast cancer patients. The development of reliable and cost-effective biomarker to evaluate the prognosis of metastatic breast cancer (MBC) patients is of great importance. S100P is a member of S100 family and has been proved to be associated with metastasis establishment.METHODS: We investigated the plasma S100P levels in 60 healthy controls, 48 primary and 273 metastatic breast cancer patients. The MBC patients were followed-up for disease progression and death up to 3.5 years after recruitment. Radiographic response of MBC patients were also analyzed for investigation on treatment monitoring value of plasma S100P level. We found a robust association between high plasma S100P level (>7 ng/mL) and poor prognosis of metastatic breast cancer (MBC) patients (median progression-free survival time: 5.0 vs. 8.7 months, log-rank test p < 0.001; median overall survival time: 22.5 vs. 31.6 months, log-rank test p < 0.001). The plasma S100P level added additional prognostic relevance to the conventional prognostication model with clinicopathological factors and CTC enumeration. The plasma S100P level decreased significantly after treatment, while the reduction correlated with the radiographic response of the MBC patients. This finding indicates the value of plasma S100P in dynamic evaluation of treatment outcome. We hereby suggest plasma S100P level as a simple and cost-effective marker for the prognosis of metastatic breast cancer.",
author = "Cike Peng and Hongda Chen and Markus Wallwiener and Caroline Modugno and Katarina Cuk and Dharanija Madhavan and Andreas Trumpp and J{\"o}rg Heil and Frederik Marm{\'e} and Juliane Nees and Sabine Riethdorf and Sarah Schott and Christof Sohn and Klaus Pantel and Andreas Schneeweiss and Rongxi Yang and Barbara Burwinkel",
year = "2016",
month = may,
day = "4",
doi = "10.1007/s10549-016-3776-1",
language = "English",
volume = "157",
pages = "329--38",
journal = "BREAST CANCER RES TR",
issn = "0167-6806",
publisher = "Springer New York",
number = "2",

}

RIS

TY - JOUR

T1 - Plasma S100P level as a novel prognostic marker of metastatic breast cancer

AU - Peng, Cike

AU - Chen, Hongda

AU - Wallwiener, Markus

AU - Modugno, Caroline

AU - Cuk, Katarina

AU - Madhavan, Dharanija

AU - Trumpp, Andreas

AU - Heil, Jörg

AU - Marmé, Frederik

AU - Nees, Juliane

AU - Riethdorf, Sabine

AU - Schott, Sarah

AU - Sohn, Christof

AU - Pantel, Klaus

AU - Schneeweiss, Andreas

AU - Yang, Rongxi

AU - Burwinkel, Barbara

PY - 2016/5/4

Y1 - 2016/5/4

N2 - Metastasis is the main cause of death in breast cancer patients. The development of reliable and cost-effective biomarker to evaluate the prognosis of metastatic breast cancer (MBC) patients is of great importance. S100P is a member of S100 family and has been proved to be associated with metastasis establishment.METHODS: We investigated the plasma S100P levels in 60 healthy controls, 48 primary and 273 metastatic breast cancer patients. The MBC patients were followed-up for disease progression and death up to 3.5 years after recruitment. Radiographic response of MBC patients were also analyzed for investigation on treatment monitoring value of plasma S100P level. We found a robust association between high plasma S100P level (>7 ng/mL) and poor prognosis of metastatic breast cancer (MBC) patients (median progression-free survival time: 5.0 vs. 8.7 months, log-rank test p < 0.001; median overall survival time: 22.5 vs. 31.6 months, log-rank test p < 0.001). The plasma S100P level added additional prognostic relevance to the conventional prognostication model with clinicopathological factors and CTC enumeration. The plasma S100P level decreased significantly after treatment, while the reduction correlated with the radiographic response of the MBC patients. This finding indicates the value of plasma S100P in dynamic evaluation of treatment outcome. We hereby suggest plasma S100P level as a simple and cost-effective marker for the prognosis of metastatic breast cancer.

AB - Metastasis is the main cause of death in breast cancer patients. The development of reliable and cost-effective biomarker to evaluate the prognosis of metastatic breast cancer (MBC) patients is of great importance. S100P is a member of S100 family and has been proved to be associated with metastasis establishment.METHODS: We investigated the plasma S100P levels in 60 healthy controls, 48 primary and 273 metastatic breast cancer patients. The MBC patients were followed-up for disease progression and death up to 3.5 years after recruitment. Radiographic response of MBC patients were also analyzed for investigation on treatment monitoring value of plasma S100P level. We found a robust association between high plasma S100P level (>7 ng/mL) and poor prognosis of metastatic breast cancer (MBC) patients (median progression-free survival time: 5.0 vs. 8.7 months, log-rank test p < 0.001; median overall survival time: 22.5 vs. 31.6 months, log-rank test p < 0.001). The plasma S100P level added additional prognostic relevance to the conventional prognostication model with clinicopathological factors and CTC enumeration. The plasma S100P level decreased significantly after treatment, while the reduction correlated with the radiographic response of the MBC patients. This finding indicates the value of plasma S100P in dynamic evaluation of treatment outcome. We hereby suggest plasma S100P level as a simple and cost-effective marker for the prognosis of metastatic breast cancer.

U2 - 10.1007/s10549-016-3776-1

DO - 10.1007/s10549-016-3776-1

M3 - SCORING: Journal article

C2 - 27146585

VL - 157

SP - 329

EP - 338

JO - BREAST CANCER RES TR

JF - BREAST CANCER RES TR

SN - 0167-6806

IS - 2

ER -